12 Month Price Forecast For ZOM
Distance to ZOM Price Forecasts
ZOM Price Momentum
🤔 Considering Zomedica (ZOM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 6:08 AM UTC
ZOM Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, ZOM has a consensus that is bullish. The median price target is $0.25, with forecasts ranging from $0.25 to $0.25. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With ZOM currently trading at $0.13, the median price forecast suggests a 98.4% upside. The most optimistic forecast comes from at , projecting a 98.4% upside, while at provides the most conservative target, suggesting a 98.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZOM Analyst Consensus
ZOM Price Target Range
Latest ZOM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZOM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2023 | Dawson James | Jason Kolbert | Buy | Initiates | $6.00 |
| Nov 16, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.30 | |
| Jun 17, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.50 |
Stocks Similar to Zomedica Pharmaceuticals Corp
The following stocks are similar to Zomedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zomedica Pharmaceuticals Corp (ZOM) Financial Data
Zomedica Pharmaceuticals Corp has a market capitalization of $122.79M with a P/E ratio of -3.6x. The company generates $26.08M in trailing twelve-month revenue with a -214.7% profit margin.
Revenue growth is +1.8% quarter-over-quarter, while maintaining an operating margin of -147.5% and return on equity of -23.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Zomedica Pharmaceuticals Corp (ZOM) Company Overview
About Zomedica Pharmaceuticals Corp
Develops veterinary health products for companion animals.
Zomedica Corp. generates revenue through the development and sale of diagnostic and therapeutic products aimed at veterinary practices. Their offerings include advanced diagnostic platforms and therapeutic devices that address pain and inflammation in companion animals, ensuring veterinarians have the tools necessary to provide quality care.
The company has strategic collaborations with Celsee, Inc. and Seraph Biosciences, Inc. to enhance its product offerings in cancer detection and pathogen detection systems. Zomedica was previously known as Zomedica Pharmaceuticals Corp. and rebranded in October 2020, with its headquarters located in Ann Arbor, Michigan.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
144
CEO
Mr. Larry C. Heaton II
Country
United States
IPO Year
2017
Website
www.zomedica.comZomedica Pharmaceuticals Corp (ZOM) Latest News & Analysis
Zomedica Corp. has signed a license agreement with Cresilon, Inc. to market Vetigel® hemostatic gel exclusively in the U.S. This expands Zomedica’s product offerings in veterinary health.
Zomedica's exclusive agreement to market Vetigel® strengthens its product portfolio, potentially increasing revenues and market share in the veterinary sector, which could positively impact stock performance.
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
1 month agoZomedica launched two new canine assays for its TRUFORMA Platform, bringing the total to 8 new assays in 18 months, enhancing its diagnostic offerings for veterinary health.
Zomedica's expansion of its TRUFORMA platform with new assays demonstrates growth in product offerings, potentially enhancing revenue and market position in veterinary diagnostics.
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
1 month agoZomedica Corp. has appointed Scott A. Jordan as Executive Vice President, Finance and CFO, effective January 1, 2025, enhancing its leadership team in veterinary health.
The appointment of Scott A. Jordan as CFO signals a potential shift in Zomedica's financial strategy, which may enhance operational efficiency and attract investor confidence.
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
1 month agoZomedica Corp. CEO Larry Heaton will present at the NobleCon20 conference on December 4, 2025. A webcast of the presentation will be available on their website following the event.
Zomedica's CEO presentation at a major investment conference signals potential growth opportunities and heightened investor interest, which could influence stock performance and market sentiment.
Zomedica Corp. (NYSE American: ZOM) has received company-sponsored equity research coverage from Noble Capital Markets, with the report available on Channelchek.
Noble Capital Markets initiating coverage on Zomedica Corp. could enhance visibility and credibility, potentially attracting more investors and impacting stock performance positively.
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
2 months agoZomedica Corp. launched its third equine assay for insulin testing on the TRUFORMA platform, aiding veterinarians in diagnosing Equine Metabolic Syndrome and related conditions.
Zomedica's launch of a new equine insulin assay enhances its product lineup, potentially increasing market share and revenue in the growing veterinary diagnostics sector.
Frequently Asked Questions About ZOM Stock
What is Zomedica Pharmaceuticals Corp's (ZOM) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Zomedica Pharmaceuticals Corp (ZOM) has a median price target of $0.25. The highest price target is $0.25 and the lowest is $0.25.
Is ZOM stock a good investment in 2025?
According to current analyst ratings, ZOM has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ZOM stock?
Wall Street analysts predict ZOM stock could reach $0.25 in the next 12 months. This represents a 98.4% increase from the current price of $0.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zomedica Pharmaceuticals Corp's business model?
Zomedica Corp. generates revenue through the development and sale of diagnostic and therapeutic products aimed at veterinary practices. Their offerings include advanced diagnostic platforms and therapeutic devices that address pain and inflammation in companion animals, ensuring veterinarians have the tools necessary to provide quality care.
What is the highest forecasted price for ZOM Zomedica Pharmaceuticals Corp?
The highest price target for ZOM is $0.25 from at , which represents a 98.4% increase from the current price of $0.13.
What is the lowest forecasted price for ZOM Zomedica Pharmaceuticals Corp?
The lowest price target for ZOM is $0.25 from at , which represents a 98.4% increase from the current price of $0.13.
What is the overall ZOM consensus from analysts for Zomedica Pharmaceuticals Corp?
The overall analyst consensus for ZOM is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $0.25.
How accurate are ZOM stock price projections?
Stock price projections, including those for Zomedica Pharmaceuticals Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
